Cyclooxygenase -2 expression and antitumor activity of piroxicam in canine primary renal tumors

DOI Web Site

Bibliographic Information

Other Title
  • 犬の原発性腎臓腫瘍におけるシクロオキシゲナーゼ（COX）–2の発現性およびピロキシカムの抗腫瘍効果の検討
  • イヌ ノ ゲンパツセイ ジンゾウ シュヨウ ニ オケル シクロオキシゲナーゼ(COX)-2 ノ ハツゲンセイ オヨビ ピロキシカム ノ コウシュヨウ コウカ ノ ケントウ

Search this article

Description

The antitumor activity of piroxicam and cyclooxygenase （COX）-2 expression was investigated in dogs with primary renal tumor. By immunohistochemistry, COX-2 was expressed in 42.9% （6/14） of the tumors examined. All of the tumors with positive COX-2 staining were epithelial in origin （renal adenocarcinoma and transitional cell carcinoma）, and COX-2 expression was also confirmed in metastatic tumors. COX-2 was not expressed in mesenchymal and embryonic tumors. Among dogs that were not surgically treated, those treated with piroxicam （3/8） had a significantly longer median survival than those untreated （5/8）. Among dogs that had metastasis at the time of first presentation, the median survival was significantly longer in dogs treated with piroxicam （8/16） than those without （8/16）. Tumor shrinkage at both primary and metastatic sites was confirmed in one dog treated with piroxicam alone. These results suggest possible antitumor activities of piroxicam in canine primary renal tumors.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top